Key Takeaways
- Regulatory overhang cleared, Bavla back online: EDQM, USFDA, PMG and AIFA all passed with "flying colors" in just over six months, reopening European markets for India CRAMS and already lifting Q4 orders.
- French facility start-up pain masked underlying momentum: A machine failure and trial batch failures at the new sterile fill-finish line wiped out Q4 EBITDA and dragged the full year to negative INR97 crores, but the line is now fixed and ready to contribute.
- One-off costs were deep but are now behind: INR46 crores of French losses, INR22 crores of non-routine maintenance, INR31 crores of salary catch-up and INR9 crores of IT costs hit the P&L; management says none recur in FY25.
- FY25 margin target set at 18–20% EBITDA: The company expects to exit the capex cycle, generate free cash flow and begin deleveraging, with French losses shrinking to INR35–40 crores and all other entities performing.
- What to watch next quarter: Whether the promised H2-weighted ramp materialises, the pace of French order-book conversion from the $90 mn RFP pipeline, and any insurance recovery from the French line supplier.
Regulatory Reset: Bavla & India CRAMS
- EDQM resolution: The European authority issued only 5 minor recommendations and no observations; the certificate arrived in January 2024, ending a period that had made business in Europe "challenging."
- USFDA, PMG, AIFA all cleared: USFDA audited Bavla in March 2024 with two weeks' notice and passed the plant; Japan's PMG and Italy's AIFA were also complied with, meaning all major regulators have now signed off.
- Commercial impact already visible: Existing customers who could not sell products in certain European geographies can now do so, and the company is already seeing an increase in orders for commercial supply out of Bavla.
- India CRAMS trajectory: Full-year India CRAMS revenue fell ~12% because of the EDQM overhang, but Q4 grew 16% as recovery began; management guides INR350 crores for FY25, INR400 crores for FY26, and INR450–500 crores the year after.
Arpit Vyas: "The customers who know what we need are not just happy, but they're extremely calm because they were also very anxious for all the companies in India getting such import alerts, especially at the time when the business was shifting from China to India."
French Facility: The Drag That Is Now a Tailwind
- What broke: A new sterile fill-finish line with complex automated mechanisms, supplied by a well-known German provider, suffered start-up issues including machine malfunction and trial batch failures. The line was capitalised in November 2023 but could not generate revenue in Q4.
- The P&L damage: French operations posted negative EBITDA of INR47 crores in Q4 and INR97 crores for the full year, because all expenses ran through the P&L once the asset was no longer capitalisable. INR46 crores of that full-year loss was one-off.
- Resolution and outlook: All problems have been fixed and the facility can now operate normally. Management expects the French entity to be a significant contributor to consolidated revenue and profitability in FY25, with the EBITDA loss shrinking to INR35–40 crores and breakeven targeted in FY26.
- Order pipeline: $90 million of RFPs have gone out; the company expects to fill the plant as quickly as possible. An insurance claim against the supplier and insurer is being filed, but no amount has been quantified.
Pascal Villemagne: "It was not entirely expected. Although we were using German provider for those lines, well known with a high reputation. But still, this is the start-up of greenfield facility. So it's not something that comes out of the blue just like this and you just press the button and everything works."
One-Off Costs: FY24 Clean-Up
| Item | Amount (INR crores) | Nature |
|---|---|---|
| French operations one-off | 46 | Machine malfunction and trial batch failure resolution |
| Non-routine maintenance/refurbishment | 22 | One-time overhaul of reactors and piping at an overseas site |
| Employee cost inflation catch-up | 31 | Incremental salary correction across the group |
| SaaS IT project (D365 France) | 9 | Digital transformation implementation |
| Soil reclamation provision | 4 | Netherlands site, to bring soil to manufacturing quality |
| Forex loss (notional) | 10 | Balance of Q3 notional loss not reversed in Q4 |
- Translation, not cash: Swiss franc-denominated employee costs created a translation impact of almost INR100 crores for the full year as the franc depreciated 12–13% against the rupee; this does not affect cash.
- Investor pushback: An analyst noted the one-off amounts were "quite sizable" and requested management be "a little bit more conscious about it please going forward."
Segment Performance
| Segment | Trend | Commentary |
|---|---|---|
| Carbogen Amcis CRAMS | ▼ Missed budget | Revenue shifted out of Q4 due to French machine failure and trial batch failures; cholesterol and vitamin D analogues grew 50%+ YoY in Q4. |
| India CRAMS | ▲ Recovering | Full year down ~12% on EDQM restrictions, but Q4 grew 16% as Bavla clearance unlocked commercial supply. |
| India Quats & Generics | ▼ Declined | Revenue fell from INR49 crores to INR29 crores in Q4 on agrochemical slowdown and a tough FY23 base that included deferred FY22 orders. |
| Swiss entity | ▬ Steady | Guided to 8–10% revenue growth in FY25; houses ~500 scientists doing early-stage development work that feeds the commercial pipeline. |
| U.K. entity | ▲ Low-base rebound | Guided to 40–50% growth in FY25 after a weak base; one major customer who did not manufacture in FY24 has now returned. |
| Netherlands | ▬ Margin focus | Revenue can be increased easily but the priority is profitability; raw material costs (wool grease) expected to decline, improving margins. |
Balance Sheet & Capital Allocation
- Capex cycle ending: Most large capex is complete; from FY25 onward, only routine maintenance capex and one water purification plant in Bavla remain. CWIP will keep reducing as assets are operationalised.
- Free cash flow inflection: With capex winding down, the company expects to generate free cash flow from FY25, with cash flow from operations of INR400–500 crores. Net debt should keep reducing over the next 2–3 years.
- Covenant relief: The covenant breach at Carbogen Amcis Holding was technical (driven by reported French EBITDA); the bank understands and has given in-principle approval for a 12-month covenant holiday, with the final letter expected shortly.
- Interest cost: Management is working on initiatives to reduce group interest cost, including borrowing in Swiss francs or swapping loans; barring forex fluctuations, interest cost should at worst remain at present levels.
- PAT profitability: Expected to turn positive from FY26.
Growth Levers Beyond the Fix
- ADC project advancing: The antibody-drug conjugate project has started; the company is analysing the validation batch at the end of Phase III. Revenues are already being generated from the validation campaign, with a ramp-up of volumes from FY26 to FY31 and peak demand around FY30–31.
- Soft gel plant: A brand-new soft gel facility has started operations and is developing multiple products.
- Sales force expansion: Major resources are being deployed to cover all geographical areas, and the company reports a "tremendous amount of inquiries for new projects."
- Digital transformation: SAP is going live this year, part of a broader push to enable more productivity through digital tools.
Arpit Vyas: "One analogy, which is at -- in our case is that of going through chemotherapy to get rid of the cancer. After we get rid of the cancer, the chemo will leave -- we'll have some weakness initially. But then you will be able to run faster in the wind."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Consolidated revenue growth | Minimum 10–12% growth | FY25 |
| Consolidated EBITDA margin | 18–20% (including French losses); 20% barring translation impact | FY25 |
| India CRAMS revenue | INR350 crores | FY25 |
| India CRAMS revenue | INR400 crores | FY26 |
| India CRAMS revenue | INR450–500 crores | FY27 |
| French entity EBITDA loss | INR35–40 crores (down from ~INR100 crores in FY24) | FY25 |
| French entity breakeven | EBITDA breakeven | FY26 |
| PAT profitability | Turn positive | FY26 |
| Free cash flow | Generate positive free cash flow; CFO of INR400–500 crores | FY25 |
| Net debt | Keep reducing over next 2–3 years as FCF is generated | FY25–FY27 |
| Swiss entity revenue growth | 8–10% | FY25 |
| U.K. entity revenue growth | 40–50% (low base) | FY25 |
| CRAMS revenue growth | 14–15% | FY25 |
| Capex | No major outlay beyond routine maintenance and one water plant | FY25 onward |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Consolidated revenue | ₹654 cr, +6% YoY from ₹618 cr in Q4 FY23 |
| Consolidated revenue (full year) | ₹2,616 cr, +8.5% YoY from ₹2,413 cr in FY23 |
| EBITDA (adjusted for one-offs) | ~₹100 cr, vs ₹83 cr in Q4 FY23 |
| EBITDA (full year, adjusted) | ~₹409 cr, vs ~₹414 cr in FY23 |
| Cash profit (full year) | ₹303 cr, vs ₹326 cr in FY23 |
| Cash generated from operations (full year) | ~₹400 cr |
| Carbogen Amcis CRAMS revenue | ₹449 cr, +~3% YoY |
| Carbogen Amcis CRAMS revenue (full year) | ₹1,953 cr, +15% YoY |
| Carbogen Amcis CRAMS EBITDA margin | 15.5%, vs 16% in Q4 FY23 |
| Cholesterol and vitamin D analogues revenue | ₹91 cr, +>50% YoY from ₹60 cr in Q4 FY23 |
| Cholesterol and vitamin D analogues EBITDA margin | ~25%, vs 13% in Q4 FY23 |
| India CRAMS revenue | ₹85 cr, +16% YoY from ₹73 cr in Q4 FY23 |
| India CRAMS EBITDA margin | 5.2%, vs ~2% in Q4 FY23 |
| India quats and generics revenue | ₹29 cr, vs ₹49 cr in Q4 FY23 |
| French entity negative EBITDA | ₹47 cr; full year ₹97 cr |
| French entity confirmed orders as of March 31 | €0.95 cr; highly expected from RFPs €0.7 cr; planned RFPs ~€9 cr |
| Consolidated EBITDA margin guidance for FY25 | 18% to 20% |
| Consolidated revenue growth guidance for FY25 | 10% to 12% |
| Capex guidance for FY25 | ₹2.5 cr to ₹3 cr (maintenance capex ~₹1.8 cr) |
| Total advances from customers as of March 31, 2024 | ₹634 cr |
| Capital work in progress | ₹500 cr, down from ₹996 cr in previous year |
| Net leverage ratio at Carbogen Amcis Holding | 4.8x, vs covenant of 4x |
| Economic equity ratio at Carbogen Amcis Holding | 33%, vs covenant of 40% |
| Net debt at Carbogen Amcis Holding | ~CHF10 cr |
| One-time maintenance and refurbishment expenditure | ₹22 cr |
| One-time employee cost inflation adjustment | ₹31 cr |
| SaaS IT project cost (one-off) | ₹9 cr |
| Provision for soil reclamation in Netherlands | ₹4 cr |
| Notional forex loss for full year | ₹9.69 cr |
| Goodwill write-off impact per annum | ~₹45 cr |